Regenxbio Inc. (NASDAQ:RGNX)’s share price traded down 4% on Tuesday . The company traded as low as $13.01 and last traded at $13.03, with a volume of 58,726 shares traded. The stock had previously closed at $13.57.

A number of equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Regenxbio from a “sell” rating to a “hold” rating in a research note on Wednesday, May 11th. Chardan Capital reaffirmed a “buy” rating on shares of Regenxbio in a research note on Tuesday, May 10th. Finally, Piper Jaffray Cos. set a $25.00 price target on shares of Regenxbio and gave the stock a “buy” rating in a research note on Thursday, August 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Regenxbio presently has a consensus rating of “Buy” and an average price target of $26.75.

The firm has a 50-day moving average price of $9.07 and a 200-day moving average price of $10.90. The company’s market cap is $350.13 million.

Regenxbio (NASDAQ:RGNX) last released its earnings results on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. On average, analysts expect that Regenxbio Inc. will post ($2.37) EPS for the current year.

An institutional investor recently raised its position in Regenxbio stock. RS Investment Management Co. LLC raised its position in Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned about 2.84% of Regenxbio worth $12,393,000 at the end of the most recent quarter.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.